From: Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
Variable | Univariate | Multivariate | ||||||
---|---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | OR (95% CI) | P-value | HR (95% CI) | P-value | OR (95% CI) | P-value | |
Age | ||||||||
 < 50 | Ref |  | Ref |  | Ref |  | Ref |  |
 ≥ 50 | 1.27 (1,1.61) | 0.049 | 0.78 (0.62,0.99) | 0.037 | 0.8 (0.53,1.22) | 0.302 | 0.81 (0.53,1.23) | 0.319 |
BMI | ||||||||
 < 30 | Ref |  | Ref |  | Ref |  | Ref |  |
 ≥ 30 | 1.08 (0.85,1.38) | 0.512 | 0.45 (0.36,0.58) |  < 0.001 | 0.94 (0.72,1.23) | 0.654 | 0.41 (0.3,0.56) |  < 0.001 |
Marital status | Â | Â | Â | Â | Â | Â | Â | Â |
Single | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Married | 0.87 (0.69,1.1) | 0.242 | 1.56 (1.18,2.07) | 0.002 | 1.28 (0.93,1.76) | 0.131 | 1.62 (1.14,2.3) | 0.007 |
Education level | ||||||||
 < diploma | Ref |  | Ref |  | Ref |  | Ref |  |
 ≥ diploma | 1.27 (0.95,1.71) | 0.106 | 1.82 (1.46,2.28) |  < 0.001 | 0.7 (0.53,0.91) | 0.009 | 1.13 (0.85,1.49) | 0.390 |
Family history | ||||||||
No | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Yes | 0.58 (0.41,0.82) | 0.002 | 0.48 (0.34,0.66) |  < 0.001 | 0.94 (0.64,1.37) | 0.747 | 0.66 (0.45,0.99) | 0.042 |
Menopausal status | ||||||||
Premenopausal | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Postmenopausal | 1.35 (1.07,1.72) | 0.013 | 0.79 (0.62,0.99) | 0.042 | 1 (0.66,1.53) | 0.998 | 0.63 (0.41,0.96) | 0.031 |
Pathology | Â | Â | Â | Â | Â | Â | Â | Â |
Others | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Inv. Ductal Ca | 0.89 (0.59,1.34) | 0.565 | 0.56 (0.39,0.82) | 0.003 | 0.68 (0.4,1.15) | 0.145 | 0.26 (0.15,0.44) |  < 0.001 |
Tumor size (cm) | ||||||||
 < 2 | Ref |  | Ref |  | Ref |  | Ref |  |
2–5 | 1.97 (1.41,2.76) |  < 0.001 | 0.99 (0.75,1.31) | 0.968 | 1.39 (0.85,2.28) | 0.195 | 1.13 (0.68,1.88) | 0.644 |
 > 5 | 3.2 (2.22,4.62) |  < 0.001 | 0.67 (0.48,0.93) | 0.015 | 1.99 (1.1,3.6) | 0.023 | 1.86 (0.96,3.57) | 0.064 |
Tumor grade | ||||||||
1 | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
2 | 0.8 (0.56,1.14) | 0.214 | 0.63 (0.44,0.92) | 0.015 | 1.04 (0.7,1.55) | 0.855 | 1.15 (0.75,1.75) | 0.521 |
3 | 1.51 (1.03,2.23) | 0.036 | 0.59 (0.39,0.88) | 0.010 | 1.35 (0.86,2.12) | 0.190 | 0.93 (0.57,1.52) | 0.776 |
Stage | ||||||||
I | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
II | 1.94 (1.29,2.93) | 0.002 | 1.13 (0.81,1.58) | 0.460 | 1.04 (0.52,2.05) | 0.921 | 1.3 (0.67,2.51) | 0.433 |
III | 2.22 (1.47,3.35) |  < 0.001 | 0.45 (0.32,0.65) |  < 0.001 | 0.49 (0.22,1.12) | 0.091 | 0.21 (0.09,0.48) |  < 0.001 |
LN metastasis | ||||||||
No | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Yes | 1.5 (1.15,1.96) | 0.003 | 0.53 (0.41,0.67) |  < 0.001 | 1.58 (1.04,2.39) | 0.031 | 1.15 (0.76,1.74) | 0.510 |
Molecular subtype | ||||||||
HR+/Her2− | Ref |  | Ref |  | Ref |  | Ref |  |
HR+/Her2+ | 1.53 (1.11,2.12) | 0.010 | 1.17 (0.87,1.58) | 0.295 | 1.34 (0.95,1.89) | 0.098 | 1.27 (0.9,1.8) | 0.177 |
HR−/Her2+ | 1.38 (1.01,1.89) | 0.045 | 0.38 (0.27,0.55) |  < 0.001 | 0.91 (0.6,1.39) | 0.654 | 0.22 (0.13,0.38) |  < 0.001 |
HR−/Her2− | 1.78 (1.26,2.5) | 0.001 | 1.28 (0.92,1.78) | 0.139 | 1.5 (0.94,2.39) | 0.091 | 1.08 (0.65,1.81) | 0.767 |
Type of surgery | ||||||||
MRM | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
BCS | 0.57 (0.45,0.73) |  < 0.001 | 1.51 (1.21,1.89) |  < 0.001 | 0.55 (0.41,0.75) |  < 0.001 | 0.97 (0.71,1.35) | 0.876 |
Hormone therapy | ||||||||
No | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Yes | 0.67 (0.51,0.9) | 0.007 | 1.34 (0.99,1.81) | 0.059 | 1.04 (0.7,1.56) | 0.848 | 0.98 (0.59,1.62) | 0.931 |
Radiotherapy | ||||||||
No | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Yes | 1.15 (0.79,1.67) | 0.479 | 0.89 (0.61,1.3) | 0.553 | 1.1 (0.68,1.79) | 0.699 | 0.92 (0.54,1.56) | 0.761 |
Adjuvant chemotherapy | ||||||||
No | Ref | Â | Ref | Â | Ref | Â | Ref | Â |
Yes | 0.61 (0.44,0.83) | 0.002 | 1.1 (0.83,1.45) | 0.499 | 0.55 (0.39,0.78) | 0.001 | 0.76 (0.53,1.1) | 0.144 |